Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia

Kapadia, Muneera R.; Chow, Lesley W.; Tsihlis, Nick D.; Ahanchi, Sadaf S.; Eng, Jason W.-L.; Murar, Jozef; Martinez, Janet; Popowich, Daniel A.; Jiang, Qun; Hrabie, Joseph A.; Saavedra, Joseph E.; Keefer, Larry K.; Hulvat, James F.; Stupp, Samuel I.; Kibbe, Melina R.

doi:10.1016/j.jvs.2007.09.005

Cited by 124 publications

(120 citation statements)

References 48 publications

Supporting

Mentioning

115

Contrasting

Order By: Relevance

“…The neck was shaved and prepped with betadine and alcohol (75%). Following a midline neck incision, the rat carotid artery balloon injury model was performed using a 2F Fogarty catheter (generously provided by Edwards Lifesciences), as previously described (2,24,36,39). After injury and restoration of blood flow, 10 mg of the diazeniumdiolate NO donor disodium 1-[(2-carboxylato)pyrrolidin-1-yl]diazen-1-ium-1,2-diolate (PROLI/NO) was applied evenly to the external surface of the injured common carotid artery of rats in the treatment group, and the neck incision was closed.…”

Section: Methodsmentioning

confidence: 99%

“…Carotid arteries were harvested at 14 days for morphometric analysis, at which time blood was collected to measure insulin, glucose, cholesterol, and triglyceride levels. PROLI/NO was used as the diazeniumdiolate for the in vivo experiments, as it is the diazeniumdiolate NO donor that we have consistently demonstrated to be superior at inhibiting neointimal hyperplasia, compared with other diazeniumdiolates, and it is the NO donor used in our laboratory's prior study on type 2 diabetes (2,24,36).…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes

Varu

Ahanchi

Hogg

et al. 2010

American Journal of Physiology-Heart and Circulatory Physiology

Self Cite

View full text Add to dashboard Cite

LK, Kibbe MR. Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes. Am J Physiol Heart Circ Physiol 299: H772-H779, 2010. First published June 18, 2010; doi:10.1152/ajpheart.01234.2009.-Diabetes confers greater restenosis from neointimal hyperplasia following vascular interventions. While localized administration of nitric oxide (NO) is known to inhibit neointimal hyperplasia, the effect of NO in type 1 diabetes is unknown. Thus the aim of this study was to determine the efficacy of NO following arterial injury, with and without exogenous insulin administration. Vascular smooth muscle cells (VSMC) from lean Zucker (LZ) rats were exposed to the NO donor, DETA/NO, following treatment with different glucose and/or insulin concentrations. DETA/NO inhibited VSMC proliferation in a concentration-dependent manner to a greater extent in VSMC exposed to normal-glucose vs. high-glucose environments, and even more effectively in normal-glucose/high-insulin and high-glucose/high-insulin environments. G 0/G1 cell cycle arrest and cell death were not responsible for the enhanced efficacy of NO in these environments. Next, type 1 diabetes was induced in LZ rats with streptozotocin. The rat carotid artery injury model was performed. Type 1 diabetic rats experienced no significant reduction in neointimal hyperplasia following arterial injury and treatment with the NO donor PROLI/NO. However, daily administration of insulin to type 1 diabetic rats restored the efficacy of NO at inhibiting neointimal hyperplasia (60% reduction, P Ͻ 0.05). In conclusion, these data demonstrate that NO is ineffective at inhibiting neointimal hyperplasia in an uncontrolled rat model of type 1 diabetes; however, insulin administration restores the efficacy of NO at inhibiting neointimal hyperplasia. Thus insulin may play a role in regulating the downstream beneficial effects of NO in the vasculature.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes

Varu

Ahanchi

Hogg

et al. 2010

American Journal of Physiology-Heart and Circulatory Physiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Protein was quantified at 1,3,5,7,21,29,46,53,70,95,122, and 141 hours after the SHH-PA was formed (n = 4). Forty-two percent of SHH protein (2.61 µg ± 0.68) came off in the first hour after PA formation ( Figure 3A).…”

Section: Quantification Of Shh Protein Diffusion From Pa In Vitromentioning

confidence: 99%

“…The protein structure is protected within the gel matrix, and no chemical modification of the protein is necessary [1,7,8]. While recently developed, this type of nano-scaffold has been used successfully in vivo to deliver vascular endothelial growth factor (VEGF) in other tissues for angiogenesis induction [1,7], and to maintain high local transforming growth factor beta (TGF-β1) concentrations for mesenchymal stem cell differentiation [3,4]. In this study, we propose to utilize PA methodology to deliver a previously identified apoptosis suppressant to the penis to prevent the development of erectile dysfunction (ED) in a prostatectomy rat model.…”

Section: Introductionmentioning

confidence: 99%

755 Peptide Amphiphile Nanofiber Delivery of Sonic Hedgehog Protein to Reduce Smooth Muscle Apoptosis in the Penis After Cavernous Nerve Resection

Bond¹,

Angeloni²,

Harrington³

et al. 2011

Journal of Urology

View full text Add to dashboard Cite

show abstract

“…Combining nanofiber delivery vehicles with NO chemistry can create a novel, more potent NO-releasing therapy that can be used clinically. Primary experiment showed that the spontaneously self-assembling NO-releasing nanofiber gels can be used to prevent neointimal hyperplasia [119][120].…”

Section: Stem Cell Nanotechnology For the Treatment Of Neurodegeneratmentioning

confidence: 99%

Advances of Nanotechnology in the Stem Cells Research and Development

Ji¹,

Ruan²,

Cui³

2010

Nano BioMed ENG

View full text Add to dashboard Cite

In decades, stem cell nanotechnology has become a new promising field for stem cell research and development. So, stem cell nanotechnology has attracted lots of researchers' attention and made great progress. The unique properties of nanomaterials and nanostructures which applied in the fundamental research of stem cell-based therapies have been recognized. Nanomaterials and nanotechnology have been highlighted as promising candidates for efficient control over proliferation and differentiation of stem cells, revolutionizing the treatment of neurodegenerative disorders, neuroprotection in traumatic brain injury, improving the osteospecific differentiation and function, tissue engineering scaffold, dental implant application, drug delivery, gene therapy and cell imaging or tracking. Here we summarize the main progress in this field, explore the application prospects in injuries, diseases, regenerative medicine, etc. and discuss the methods and challenges with the aim of improving application of nanotechnology in the stem cell research and development.

show abstract

Nitric oxide and nanotechnology: A novel approach to inhibit neointimal hyperplasia

Cited by 124 publications

References 48 publications

Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes

Insulin enhances the effect of nitric oxide at inhibiting neointimal hyperplasia in a rat model of type 1 diabetes

755 Peptide Amphiphile Nanofiber Delivery of Sonic Hedgehog Protein to Reduce Smooth Muscle Apoptosis in the Penis After Cavernous Nerve Resection

Advances of Nanotechnology in the Stem Cells Research and Development

Contact Info

Product

Resources

About